Table 1

Change in disease activity in patients with RA, PsA and AS transitioned from reference infliximab to biosimilar infliximab, SB2

	Time period	Patients (n)	Mean change (95% CI) in disease activity from baseline
RA	M0–6	44	∆DAS-28=0.0 (–0.4 to 0.4)
RA	M0–12	40	∆DAS-28=0.2 (–0.2 to 0.6)
PsA	M0–6	13	∆DAS-28=0.1 (–0.5 to 0.7)
PsA	M0–12	13	∆DAS-28=−0.2 (–0.8 to 0.4)
AS	M0–6	141	∆BASDAI=−0.3 (–0.6 to 0.0)
AS	M0–12	135	∆BASDAI=0.1 (–0.2 to 0.4)

AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DAS, Disease Activity Score 28 including 28-joint count; M, Month; PsA, psoriatic arthritis; RA, rheumatoid arthritis.